Compare Stocks

Date Range: 

 BioMarin PharmaceuticalElanco Animal HealthOno PharmaceuticalGrifolsTeva Pharmaceutical Industries
SymbolNASDAQ:BMRNNYSE:ELANOTCMKTS:OPHLFNASDAQ:GRFSNYSE:TEVA
Price Information
Current Price$77.77$32.88$25.90$18.23$10.40
52 Week RangeBuyHoldN/ABuyHold
MarketRank™
Overall Score2.11.41.11.31.6
Analysis Score4.31.20.00.02.1
Community Score3.12.22.22.12.6
Dividend Score0.00.00.01.70.0
Ownership Score1.71.70.00.00.8
Earnings & Valuation Score1.31.93.12.52.5
Analyst Ratings
Consensus RecommendationBuyHoldN/ABuyHold
Consensus Price Target$118.05$31.86N/AN/A$11.78
% Upside from Price Target51.79% upside-3.09% downsideN/AN/A13.25% upside
Trade Information
Market Cap$14.21 billion$15.55 billion$13.32 billion$12.53 billion$11.36 billion
Beta0.710.861.060.591.49
Average Volume1,215,5063,884,412457867,1299,557,240
Sales & Book Value
Annual Revenue$1.70 billion$3.07 billion$2.69 billion$5.71 billion$16.89 billion
Price / Sales8.345.064.952.190.67
Cashflow$0.60 per share$2.00 per share$1.18 per share$1.57 per share$3.50 per share
Price / Cash130.2216.4821.9211.582.97
Book Value$17.38 per share$14.87 per share$10.16 per share$11.15 per share$13.79 per share
Price / Book4.472.212.551.630.75
Profitability
Net Income$-23,850,000.00$67.90 million$549.28 million$700.16 million$-998,000,000.00
EPS$0.07$1.06$1.09$1.17$2.31
Trailing P/E Ratio17.80N/A23.5516.28N/A
Forward P/E Ratio146.7436.5315.8912.074.09
P/E Growth3.894.13N/A1.300.87
Net Margins45.74%-8.45%22.14%12.79%-24.17%
Return on Equity (ROE)4.34%3.43%11.29%10.65%19.32%
Return on Assets (ROA)2.84%2.04%9.71%4.79%4.89%
Dividend
Annual PayoutN/AN/AN/A$0.14N/A
Dividend YieldN/AN/AN/A0.77%N/A
Three-Year Dividend GrowthN/AN/AN/A-49.65%N/A
Payout RatioN/AN/AN/A11.97%N/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.26%0.67%N/A0.95%2.22%
Current Ratio3.20%1.75%2.78%2.93%1.00%
Quick Ratio2.38%0.90%2.33%1.33%0.63%
Ownership Information
Institutional Ownership Percentage97.65%86.83%N/A15.15%51.20%
Insider Ownership Percentage2.15%0.12%N/AN/A0.56%
Miscellaneous
Employees3,05910,2003,56023,65537,100
Shares Outstanding182.74 million472.80 million514.12 million687.55 million1.09 billion
Next Earnings Date8/3/2021 (Estimated)N/A5/11/2021 (Estimated)7/29/2021 (Estimated)8/4/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
The Top 5 Trades of Francisco Garcia Parames FirmThe Top 5 Trades of Francisco Garcia Parames' Firm
finance.yahoo.com - May 7 at 4:44 PM
Contraceptives Market Revenue, Industry Growing Demand, Size, Share, Business Opportunities and Forecast - 2027Contraceptives Market Revenue, Industry Growing Demand, Size, Share, Business Opportunities and Forecast - 2027
openpr.com - May 7 at 11:43 AM
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call TranscriptCorcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 6:43 AM
Weight Loss Drugs Market SWOT Analysis by Key Players- Teva, Sandoz, RocheWeight Loss Drugs Market SWOT Analysis by Key Players- Teva, Sandoz, Roche
sbwire.com - May 6 at 7:01 PM
Interesting TEVA Call Options For June 25thInteresting TEVA Call Options For June 25th
nasdaq.com - May 6 at 7:01 PM
Worldwide Gastroparesis Industry to 2027 - Surging Investments and Financial Assistance for Research Presents OpportunitiesWorldwide Gastroparesis Industry to 2027 - Surging Investments and Financial Assistance for Research Presents Opportunities
markets.businessinsider.com - May 6 at 2:00 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2021 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 5 at 4:38 PM
Zacks: Brokerages Anticipate Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Announce Earnings of $0.58 Per ShareZacks: Brokerages Anticipate Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Announce Earnings of $0.58 Per Share
americanbankingnews.com - May 5 at 12:38 PM
Teva Kicks Off Trial To Revoke Bayers Cancer Drug PatentTeva Kicks Off Trial To Revoke Bayer's Cancer Drug Patent
law360.com - May 4 at 6:21 PM
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United StatesTeva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
finance.yahoo.com - May 4 at 1:21 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Neutral at UBS GroupTeva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Neutral at UBS Group
americanbankingnews.com - May 4 at 8:08 AM
Teva Pharmaceutical Industries (NYSE:TEVA) Lowered to Neutral at UBS GroupTeva Pharmaceutical Industries (NYSE:TEVA) Lowered to Neutral at UBS Group
marketbeat.com - May 4 at 7:10 AM
Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual ...Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual ...
apnews.com - May 3 at 12:19 PM
Notable ETF Inflow Detected - IDEV, CCEP, TEVA, FUTUNotable ETF Inflow Detected - IDEV, CCEP, TEVA, FUTU
nasdaq.com - May 3 at 12:19 PM
Q2 2021 EPS Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Lowered by AnalystQ2 2021 EPS Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Lowered by Analyst
americanbankingnews.com - May 3 at 1:44 AM
Q2 2021 EPS Estimates for Teva Pharmaceutical Industries Limited Cut by Analyst (NYSE:TEVA)Q2 2021 EPS Estimates for Teva Pharmaceutical Industries Limited Cut by Analyst (NYSE:TEVA)
americanbankingnews.com - May 3 at 1:44 AM
Interesting TEVA Call Options For June 11thInteresting TEVA Call Options For June 11th
nasdaq.com - April 29 at 3:48 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Trading 4.8% Higher  on Better-Than-Expected EarningsTeva Pharmaceutical Industries (NYSE:TEVA) Trading 4.8% Higher on Better-Than-Expected Earnings
americanbankingnews.com - April 29 at 12:34 PM
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock DownTEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
finance.yahoo.com - April 29 at 10:09 AM
Teva Pharmaceutical Industries (NYSE:TEVA) Releases  Earnings Results, Beats Estimates By $0.08 EPSTeva Pharmaceutical Industries (NYSE:TEVA) Releases Earnings Results, Beats Estimates By $0.08 EPS
americanbankingnews.com - April 28 at 9:00 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY21 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) Releases FY21 Earnings Guidance
americanbankingnews.com - April 28 at 7:24 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2021 Earnings GuidanceTeva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2021 Earnings Guidance
americanbankingnews.com - April 28 at 6:32 PM
Astellas Adds 2nd Patent To Urinary Drug IP Fight With TevaAstellas Adds 2nd Patent To Urinary Drug IP Fight With Teva
law360.com - April 28 at 1:44 PM
Teva Pharmaceutical Industries Limited 2021 Q1 - Results - Earnings Call PresentationTeva Pharmaceutical Industries Limited 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 28 at 12:18 PM
Teva beats analysts on Q1 profit, misses on revenueTeva beats analysts on Q1 profit, misses on revenue
en.globes.co.il - April 28 at 8:43 AM
Teva Pharm first-quarter profit meets estimates, reaffirms 2021 outlookTeva Pharm first-quarter profit meets estimates, reaffirms 2021 outlook
msn.com - April 28 at 8:43 AM
3 ADRs to Spruce up Your International Exposure3 ADRs to Spruce up Your International Exposure
marketbeat.com - April 27 at 3:49 PM
DateCompanyBrokerageAction
4/28/2021BioMarin PharmaceuticalWedbushReiterated Rating
4/26/2021BioMarin PharmaceuticalCredit Suisse GroupInitiated Coverage
4/26/2021BioMarin PharmaceuticalMorgan StanleyLower Price Target
3/8/2021BioMarin PharmaceuticalEvercore ISIUpgrade
3/8/2021BioMarin PharmaceuticalCanaccord GenuityLower Price Target
3/1/2021BioMarin PharmaceuticalRobert W. BairdReiterated Rating
11/6/2020BioMarin PharmaceuticalSVB LeerinkLower Price Target
9/10/2020BioMarin PharmaceuticalTruistLower Price Target
8/20/2020BioMarin PharmaceuticalOppenheimerLower Price Target
8/20/2020BioMarin PharmaceuticalJefferies Financial GroupLower Price Target
8/20/2020BioMarin PharmaceuticalWilliam BlairReiterated Rating
8/19/2020BioMarin PharmaceuticalCitigroupDowngrade
8/19/2020BioMarin PharmaceuticalRoyal Bank of CanadaDowngrade
8/19/2020BioMarin PharmaceuticalStifel NicolausDowngrade
3/29/2021Elanco Animal HealthGabelliReiterated Rating
3/22/2021Elanco Animal HealthRaymond JamesReiterated Rating
12/9/2020Elanco Animal HealthArgusDowngrade
11/17/2020Elanco Animal HealthCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
11/9/2020Elanco Animal HealthBarclaysDowngrade
8/4/2020Elanco Animal HealthThe Goldman Sachs GroupInitiated Coverage
7/27/2020Elanco Animal HealthCleveland ResearchDowngrade
7/20/2020Elanco Animal HealthBank of AmericaBoost Price Target
4/27/2021GrifolsBerenberg BankReiterated Rating
4/20/2021GrifolsDeutsche Bank AktiengesellschaftInitiated Coverage
3/17/2021GrifolsHSBCUpgrade
3/2/2021GrifolsJPMorgan Chase & Co.Reiterated Rating
5/4/2021Teva Pharmaceutical IndustriesUBS GroupDowngrade
11/6/2020Teva Pharmaceutical IndustriesBMO Capital MarketsLower Price Target
6/1/2020Teva Pharmaceutical IndustriesSunTrust BanksUpgrade
5/8/2020Teva Pharmaceutical IndustriesCantor FitzgeraldReiterated Rating
4/15/2020Teva Pharmaceutical IndustriesPiper SandlerLower Price Target
3/5/2020Teva Pharmaceutical IndustriesWells Fargo & CompanyBoost Price Target
2/24/2020Teva Pharmaceutical IndustriesEdward JonesDowngrade
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.